Network pharmacology-based exploration of therapeutic targets and key pathways of gastrodin in lung cancer
Integrate Medicine · 30.04.2025
DOI: 10.61958/imcl2577 ↗Kurz gefasst
Fachartikel in der Zeitschrift Integrate Medicine, online erschienen am 30.04.2025. Verfasst von Yuan Zhou und 1 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
Objective
This study aims to investigate the potential targets and mechanisms of gastrodin (GAS) in the treatment of lung cancer using a network pharmacology approach.
Methods
Targets related to the lung, lung cancer, and GAS were retrieved from the National Library of Medicine, GeneCards, and ETCM databases. The collected data were analyzed using Venny, DAVID, and Cytoscape software. A regulatory network involving lung, lung cancer, and GAS-related targets was constructed, and ten core targets were identified based on degree values. Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted for the intersecting targets using the DAVID database, with significance set at P < 0.05. A lung–lung cancer–GAS–KEGG pathway network was subsequently established for further analysis.
Results
A total of 35 intersecting targets were identified, and ten key targets were screened, including interleukin-6 (IL6), interleukin-1 beta (IL1B), nuclear factor kappa B subunit 1 (NFKB1), insulin-like growth factor 1 (IGF1), glycogen synthase kinase 3 beta (GSK3B), galectin-3 (LGALS3), glycogen phosphorylase L (PYGL), coagulation factor III (F3), prostaglandin-endoperoxide synthase 1 (PTGS1), and superoxide dismutase 1 (SOD1). GO analysis yielded 40 biological process (BP), 6 cellular component (CC), and 13 molecular function (MF) terms. KEGG pathway analysis identified 48 significantly enriched pathways, including starch and sucrose metabolism, insulin resistance, the hypoxia-inducible factor 1 (HIF-1) signaling pathway, and carbohydrate digestion and absorption.
Conclusions
GAS may exert therapeutic effects on lung cancer by targeting IL6, IL1B, NFKB1, IGF1, GSK3B, LGALS3, and related molecules, primarily through pathways such as starch and sucrose metabolism, insulin resistance, and the HIF-1 signaling pathway.
Zitieren
APA
Zhou, Y., & Cheng, F. (2025). Network pharmacology-based exploration of therapeutic targets and key pathways of gastrodin in lung cancer. Integrate Medicine. https://doi.org/10.61958/imcl2577
Vancouver
Zhou Y, Cheng F. Network pharmacology-based exploration of therapeutic targets and key pathways of gastrodin in lung cancer. Integrate Medicine. 2025. doi:10.61958/imcl2577
BibTeX
@article{Zhou2025,
author = {Zhou, Yuan and Cheng, Fang},
title = {Network pharmacology-based exploration of therapeutic targets and key pathways of gastrodin in lung cancer},
journal = {Integrate Medicine},
year = {2025},
doi = {10.61958/imcl2577}
}
EUVIMED